Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials-Reference-Cited by-同舟云学术

Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials

Published:2019-11-30 Issue:3 Volume:146 Page:721-737
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Luo Jing,Dai Xinchi,Hu Hua,Chen Jie,Zhao Lujun,Yang Changyong,Sun Jifeng,Zhang Lianmin,Wang Qian,Xu Shilei,Xu Yue,Liu Ningbo^ORCID,Ying Guoguang,Wang Ping

Funder

Tianjin Natural Science Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-019-03097-6.pdf

Reference52 articles.

1. BRCA2 mutation linked to lung cancer risk (2014) Cancer Discov 4:OF1 https://doi.org/10.1158/2159-8290.cd-nb2014-096

2. Bryant HE et al (2009) PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 28:2601–2615. https://doi.org/10.1038/emboj.2009.206

3. Chen J, Peng H, He J, Huan X, Miao Z, Yang C (2014) Synthesis of isoquinolinone-based tricycles as novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Bioorg Med Chem Lett 24:2669–2673. https://doi.org/10.1016/j.bmcl.2014.04.061